Development of Mouse Models of Ovarian Cancer for Studying Tumor Biology and Testing Novel Molecularly Targeted Therapeutic Strategies

2011 ◽  
Author(s):  
Kathleen R. Cho ◽  
Alnawaz Rehemtulla
Keyword(s):  
Ovarian Cancer ◽  
Mouse Models ◽  
Tumor Biology ◽  
Therapeutic Strategies ◽  
Targeted Therapeutic

scholarly journals Roads to the strategic targeting of ovarian cancer treatment

Reproduction ◽  
2021 ◽  
Vol 161 (1) ◽  
pp. R1-R11
Author(s):  
Griselda Irusta
Keyword(s):  
Ovarian Cancer ◽  
Ovarian Tumor ◽  
Tumor Biology ◽  
Therapeutic Strategies ◽  
High Rate ◽  
Ovarian Cancer Cells ◽  
Antiangiogenic Agents ◽  
Molecular Events ◽  
Platinum Based Chemotherapy ◽  
Canonical Wnt

Although ovarian cancer mortality rates have slightly declined in the last 40 years, ovarian cancer continues to be the eighth cause of cancer death in women. Ovarian cancer is characterized by its high response to treatments but also by its high rate of recurrence. Although treatments are limited to cytoreductive surgery and platinum-based chemotherapy, other therapies using antiangiogenic agents and poly (ADP-ribose) polymerase inhibitors are being tested. Nevertheless, these therapeutic strategies have had poor results and new potential targets and approaches are thus needed. The present review focuses on the recent evidence on antiangiogenic strategies in ovarian cancer cells and on the mechanisms governed by Notch and β-catenin proteins. It also describes the concept of ‘vascular normalization’ by using the platelet-derived growth factor, PDGFB, molecule as a tool to regulate ovarian tumor angiogenesis and thus improve ovarian tumor treatment. It has been reported that alterations in the Notch system components and changes in the canonical Wnt/β-catenin signaling, the other pathway of our interest, are relevant to molecular events that contribute to ovarian cancer development. Thus, in this review, we consider these aspects of the ovarian tumor biology as potential new therapeutic strategies for the treatment of this disease.

Tumor biology driven treatment selection in primary ovarian cancer

2014 ◽  
Vol 74 (S 01) ◽  
Author(s):  
F Arnold ◽  
D Margraf ◽  
O Hoffmann ◽  
K von Dehn-Rotfelser ◽  
I Funke ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Tumor Biology ◽  
Treatment Selection ◽  
Primary Ovarian Cancer

Targeting Membrane Receptors of Ovarian Cancer Cells for Therapy

2019 ◽  
Vol 19 (6) ◽  
pp. 449-467
Author(s):  
Zhiquan Liang ◽  
Ziwen Lu ◽  
Yafei Zhang ◽  
Dongsheng Shang ◽  
Ruyan Li ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Cells ◽  
Receptor Binding ◽  
Cytoreductive Surgery ◽  
Therapeutic Strategies ◽  
Membrane Receptors ◽  
Ovarian Cancer Cells ◽  
Advanced Stage ◽  
Targeted Therapeutics ◽  
Cellular Processes

Ovarian cancer is a leading cause of death worldwide from gynecological malignancies, mainly because there are few early symptoms and the disease is generally diagnosed at an advanced stage. In addition, despite the effectiveness of cytoreductive surgery for ovarian cancer and the high response rates to chemotherapy, survival has improved little over the last 20 years. The management of patients with ovarian cancer also remains similar despite studies showing striking differences and heterogeneity among different subtypes. It is therefore clear that novel targeted therapeutics are urgently needed to improve clinical outcomes for ovarian cancer. To that end, several membrane receptors associated with pivotal cellular processes and often aberrantly overexpressed in ovarian cancer cells have emerged as potential targets for receptor-mediated therapeutic strategies including specific agents and multifunctional delivery systems based on ligand-receptor binding. This review focuses on the profiles and potentials of such strategies proposed for ovarian cancer treatment and imaging.

scholarly journals Novel Therapeutic Strategies for Ovarian Cancer Stem Cells

2020 ◽  
Vol 10 ◽  
Author(s):  
Nastassja Terraneo ◽  
Francis Jacob ◽  
Anna Dubrovska ◽  
Jürgen Grünberg
Keyword(s):  
Ovarian Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Therapeutic Strategies ◽  
Ovarian Cancer Stem Cells ◽  
Novel Therapeutic Strategies ◽  
Novel Therapeutic

scholarly journals Gene therapy for ovarian cancer using carbonyl reductase 1 DNA with a polyamidoamine dendrimer in mouse models

2015 ◽  
Vol 23 (1) ◽  
pp. 24-28 ◽  
Author(s):  
A Kobayashi ◽  
Y Yokoyama ◽  
Y Osawa ◽  
R Miura ◽  
H Mizunuma
Keyword(s):  
Ovarian Cancer ◽  
Gene Therapy ◽  
Mouse Models ◽  
Carbonyl Reductase ◽  
Polyamidoamine Dendrimer
Sign in / Sign up

Export Citation Format

Share Document